Evicenter
Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in Herpes zoster prevention
Manufacturer
GlaxoSmithKline Biologicals; GlaxoSmithKline
Prescribing information
Shingrix (opens in a new tab)
Questions
47
Last updated

All questions

Clinical trials: Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention

15 questions · 5 sources

Clinical trials

How were the Shingrix ZOE-50 and ZOE-70 trials designed?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

“ZOE-50 (Study 1) Design: Data from ZOE-50 (NCT01165177), a placebo-controlled, observer-blind phase 3 trial conducted in 18 countries in which subjects ≥50 years old were randomized to receive 2 doses (0 and 2 months) of either SHINGRIX (N=7698) or placebo (N=7713). A total of 7344 and 7415 subjects who received SHINGRIX and placebo, respectively, were included in the mTVC analysis. Subjects were followed for the development of HZ and PHN for a median of 3.1 years (range: 0 to 3.7 years).1,3 ZOE-70 (Study 2) Design: Data from ZOE-70 (NCT01165229), a placebo-controlled, observer-blind phase 3 trial conducted in 18 countries in which subjects ≥70 years old were randomized to receive 2 doses (0 and 2 months) of either SHINGRIX (N=6950) or placebo (N=6950). A total of 6541 and 6622 subjects who received SHINGRIX and placebo, respectively, were included in the mTVC analysis. Subjects were followed for the development of HZ and PHN for a median of 3.9 years (range: 0 to 4.5 years).1,2 The primary efficacy analysis (mTVC) in ZOE-50 and ZOE-70 included all subjects who did not develop a confirmed case of HZ within 1 month after the second dose.1 Pooled Analysis of ZOE-50 (Study 1) and ZOE-70 (Study 2): Data from ZOE-50 and ZOE-70 were combined in a prespecified pooled analysis. A total of 8250 and 8346 subjects ≥70 years of age who received SHINGRIX and placebo, respectively, were included in the mTVC. Subjects were followed for the development of HZ and PHN for a median of 4.0 years (range: 0 to 4.5 years).1,4 The studies excluded subjects who were immunocompromised, had a history of HZ, were previously vaccinated against varicella or HZ, and patients whose survival was not expected to be at least 4 years, or with conditions that might interfere with study evaluations.1” (opens the source at this quote in a new tab)

Has Shingrix been studied in kidney transplant recipients?

Applies to Adult renal transplant recipients receiving maintenance immunosuppressive therapy (ZOSTER-041)

Note: The study evaluated immunogenicity and safety; the Prescribing Information reports no efficacy result for renal transplant recipients.

Has Shingrix been studied in adults with HIV?

Applies to Adults aged 18 years and older with HIV (ZOSTER-015)

Note: The study used a 3-dose schedule; the page states that a third dose is outside the approved dosing schedule.

Study results

How effective is Shingrix vs placebo in adults 50 and older (ZOE-50)?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

How effective is Shingrix by age group in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Note: Results for ages 50 to 59 and 60 to 69 are from ZOE-50; results for ages 70 to 79 and 80 and older are from the pooled ZOE-50 and ZOE-70 analysis. Each comparison is with placebo in the modified Total Vaccinated Cohort. Median follow-up was 3.1 years in ZOE-50 and 4.0 years in the pooled analysis.

How effective is Shingrix vs placebo in adults 70 and older?

Applies to Adults aged 70 years and older (ZOE-70 and the pooled ZOE-50 and ZOE-70 analysis)

Note: The pooled analysis combined ZOE-50 (Study 1) and ZOE-70 (Study 2); the fourth-year result is a descriptive analysis of ZOE-70. The pooled median follow-up of 4.0 years is from the Efficacy Data page of the Shingrix HCP site.

Does Shingrix reduce postherpetic neuralgia (PHN) vs placebo in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Note: The first passage is from ZOE-50 (median follow-up 3.1 years) and the second from ZOE-70 (median follow-up 3.9 years). Shingrix is indicated for prevention of herpes zoster; the HCP site states that it is not indicated for the prevention of PHN or other herpes zoster-related complications.

Did Shingrix reduce shingles pain medication use vs placebo in adults 70 and older?

Applies to Adults aged 70 years and older (ZOE-70 and the pooled ZOE-50 and ZOE-70 analysis)

Note: This result is from ZOE-70 (Study 2) and is limited to participants who developed confirmed herpes zoster.

How effective is Shingrix vs placebo after autologous stem cell transplant?

Applies to Immunocompromised adults aged 18 years and older who received an autologous hematopoietic stem cell transplant 50 to 70 days before the first dose (NCT01610414)

Note: The table is from the immunocompromised Efficacy Data page of the Shingrix HCP site; N/n gives the number of subjects in each group and the number with at least 1 confirmed herpes zoster episode.

Does Shingrix reduce PHN vs placebo after autologous stem cell transplant?

Applies to Immunocompromised adults aged 18 years and older who received an autologous hematopoietic stem cell transplant 50 to 70 days before the first dose (NCT01610414)

Did Shingrix shorten shingles pain vs placebo after autologous stem cell transplant?

Applies to Immunocompromised adults aged 18 years and older who received an autologous hematopoietic stem cell transplant 50 to 70 days before the first dose (NCT01610414)

Note: The comparison is limited to auHSCT study participants who developed confirmed herpes zoster.

How effective was Shingrix vs placebo in hematologic malignancies (post hoc analysis)?

Applies to Immunocompromised adults aged 18 years and older with hematologic malignancies vaccinated during or within 6 months of immunosuppressive chemotherapy (NCT01767467)

Note: This efficacy result is from a post hoc analysis, and postherpetic neuralgia was not a study endpoint.

Long-term results

How effective is Shingrix vs placebo in year 4 in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Note: Both results are descriptive analyses compared with placebo: the first from ZOE-50 (adults 50 and older) and the second from ZOE-70 (adults 70 and older).

What did Shingrix long-term follow-up show through about 11 years in adults 50+?

Applies to Adults aged 50 years and older vaccinated in ZOE-50 or ZOE-70 and followed in the long-term follow-up study (ZOSTER-049)

Note: The long-term follow-up results are descriptive and compare vaccinated participants with a historical control constructed from the ZOE-50 and ZOE-70 placebo groups; the page lists the limitations of this method.

How effective is Shingrix long term by age at vaccination?

Applies to Adults aged 50 years and older vaccinated in ZOE-50 or ZOE-70 and followed in the long-term follow-up study (ZOSTER-049)

Note: These are descriptive long-term follow-up results compared with a historical control from the ZOE-50 and ZOE-70 placebo groups, starting at a median of 5.6 years and ending at a median of 11.4 years after vaccination.